ITOS Form 4: CFO Equity Cashed Out, CVR Issued in Merger
Rhea-AI Filing Summary
Matthew Gall, Chief Financial Officer of iTeos Therapeutics (ITOS), reported transactions tied to the company’s merger. At the effective time of the merger, each outstanding share was converted into $10.047 in cash plus one non-transferable contingent value right (CVR). The Form 4 reports the disposition/cancellation of 89,429 common shares and cancellation of multiple stock options and restricted stock units, with the filer showing 0 shares beneficially owned following the transactions. In-the-money options were canceled in exchange for cash equal to the difference between $10.047 and each option’s exercise price multiplied by the underlying shares, plus one CVR per share. The reported option and underlying share counts include 9,063, 135,937, 42,388, 8,123 and 252,135 units/options as described in the filing.
Positive
- Merger consideration is cash-based at a stated price of $10.047 per share, providing immediate liquidity to holders
- In-the-money options were cashed out, which removes potential future dilution tied to those options
- Accelerated vesting applied per plan terms, ensuring contractual treatment for affected service providers
Negative
- Reporting person reported 0 shares beneficially owned following the transaction, indicating full disposition of holdings disclosed here
- Large quantities of options and RSUs were canceled, which may concern stakeholders tracking executive equity retention post-transaction
Insights
TL;DR: Insider disposals reflect merger consideration conversion, not open-market sales; cash paid per share is $10.047 plus a CVR.
The Form 4 documents that the CFO’s equity holdings were settled under the merger agreement terms rather than through market trades. From a financial perspective, conversion at a fixed cash price simplifies payout valuation for these holdings; holders of in-the-money options received immediate cash equivalent value for intrinsic worth, reducing future dilution risk. The filings report substantial option and RSU cancellations, which removes those potential shares from future share count post-merger.
TL;DR: The transactions follow contractually mandated merger mechanics and accelerated vesting provisions, raising no governance red flags on their face.
The disclosures indicate the Compensation Committee applied pre-agreed accelerated vesting and option cash-out provisions contained in the merger agreement. The treatment—cash payment plus CVRs for restricted stock units and in-the-money options—is standard in controlled M&A exits. Important governance items for stakeholders are disclosure clarity and confirmation that committee actions followed plan terms; the Form 4 provides those mechanics and volumes.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option (Right to Buy) | 9,063 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 135,937 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 42,388 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 8,123 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 252,135 | $0.00 | -- |
| U | Common Stock | 89,429 | $0.00 | -- |
Footnotes (1)
- This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 18, 2025, by and among iTeos Therapeutics, Inc. (the "Company"), Concentra Biosciences LLC ("Parent"), and Concentra Merger Sub VIII, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Parent completed a tender offer for shares of common stock of the Company ("Shares") and thereafter, the Merger Sub merged with and into the Company (the "Merger"). At the effective time of the Merger (the "Effective Time"), each issued and outstanding Share was canceled and converted into the right to receive (i) $10.047 in cash per share (the "Cash Amount"); plus (ii) one non-transferable contractual contingent value right per share (each, a "CVR"), without interest and subject to applicable withholding of taxes. The amount reported in Column 4 includes 65,000 restricted stock units of the Company ("Company Restricted Stock Units," and each such restricted stock unit, a "Company Restricted Stock Unit"). Pursuant to the actions of the of the Compensation and Leadership Development Committee of the Board of Directors of the Company (the "Committee") and in accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, (A) each Company Restricted Stock Unit that was held by a Company service provider who was subject to an individual employment or other agreement and/or a Company severance and change in control plan or agreement that provides for accelerated vesting of time-based equity awards upon the occurrence of a sale of the Company or a qualifying termination of employment or service in connection with, (Continued from footnote 2) or within a specified time following, a sale of the Company (each such Company Restricted Stock Unit, an "Accelerated Vesting Restricted Stock Unit") that was then outstanding but not then vested became immediately vested in full and (B) each Accelerated Vesting Restricted Stock Unit that was then outstanding was canceled and, in exchange therefor, the holder of such canceled Company Restricted Stock Unit became entitled to receive in consideration of the cancellation of such Company Restricted Stock Unit (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the Cash Amount and (y) one CVR. Pursuant to the actions of the of the Committee and in accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, each option to purchase Shares from the Company ("Company Stock Options," and each such option, a "Company Stock Option") that was then outstanding but not then vested or exercisable and that was held by a Company service provider who was subject to an individual employment or other agreement and/or a Company severance and change in control plan or agreement that provides for accelerated vesting of time-based equity awards upon the occurrence of a sale of the Company or a qualifying termination of employment or service in connection with, or within a specified time following, a sale of the Company became immediately vested and exercisable in full. In accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, each Company Stock Option that had an exercise price per share that is less than the Cash Amount (each, an "In-the-Money Option") that was then outstanding was canceled and, in exchange therefor, the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one CVR for each Share underlying such In-the-Money Option.
